NCT07001150 Role of Silymarin in Neuroprotection and Symptom Management in Parkinson's Disease
| NCT ID | NCT07001150 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Tanta University |
| Condition | Parkinson Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2025-05-10 |
| Primary Completion | 2026-05-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 50 participants in total. It began in 2025-05-10 with a primary completion date of 2026-05-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Parkinson's disease (PD) is a leading neurodegenerative movement disorder, marked by a gradual loss of dopamine-producing neurons in the substantia nigra pars compacta (SNpc) and the accumulation of α-synuclein protein aggregates. Silymarin, a polyphenolic flavonoid renowned for its potent antioxidant properties, will be studied for its neuroprotective effects in PD.
Eligibility Criteria
Inclusion Criteria: * Age between 45 and 65 years old * Both sexes * Patients with Parkinson's disease on dopamine replacement therapy * Modified Hoehn and Yahr stage, MHY 1-4 (29) Exclusion Criteria: * Subjects \< 18 years of age * Pregnant or breastfeeding women * Suspected hypersensitivity to silymarin or multivitamins * Advanced liver disease (e.g., ascites, bleeding esophageal varices, and hepatic encephalopathy) * Subjects with morbid obesity, i.e., a Body Mass Index (BMI) \> 40 * Subjects with severe illness, e.g., multisystem failure, cancer, or poorly controlled diabetes, i.e., known diabetic with Hemoglobin A1C (HbA1C)\>7% * Current use of Silymarin or recent use within the past two weeks. * Other conditions, which, in the opinion of the investigators, make the patient unsuitable for enrollment.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07001150 clinical trial?
This trial is open to participants of all sexes, aged 45 Years or older, up to 65 Years, studying Parkinson Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07001150 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07001150 currently recruiting?
Yes, NCT07001150 is actively recruiting participants. Contact the research team at nelsherbeny@horus.edu.eg for enrollment information.
Where is the NCT07001150 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT07001150 clinical trial?
NCT07001150 is sponsored by Tanta University. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.